

International Nonproprietary Names for Pharmaceutical Substances

In accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances,¹ notice is hereby given that the following are selected as recommended international nonproprietary names.

The inclusion of a name in the lists of recommended international nonproprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.

Recommended International Nonproprietary Names (Rec. INN): List 29²

<i>Recommended International Nonproprietary Name (Latin, English)</i>	<i>Chemical Name or Description and Molecular Formulae</i>
abecarnilum abecarnil	isopropyl 6-(benzyloxy)-4-(methoxymethyl)-9H-pyrido[3,4-b]indole-3-carboxylate C ₂₄ H ₂₄ N ₂ O ₄
acemannanum acemannan	(1→4)-β-D-mannurono-2-acetamido-2-deoxy-β-D-glucosyl-β-D-mannan 3-acetate
acidum butedronicum butedronic acid	(diphosphonomethyl)succinic acid C ₈ H ₁₀ O ₁₀ P ₂
acidum gadotericum gadoteric acid	hydrogen [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)]-gadolate(1-) C ₁₆ H ₂₈ GdN ₄ O ₈
acidum pamidronicum pamidronic acid	(3-amino-1-hydroxypropylidene)diphosphonic acid C ₃ H ₁₁ NO ₇ P ₂
acidum tiludronicum tiludronic acid	[(p-chlorophenyl)thio]methylene]diphosphonic acid C ₇ H ₈ ClO ₄ P ₂ S
actisomidum actisomide	(±)-cis-4-[2-(diisopropylamino)ethyl]-4,4a,5,6,7,8-hexahydro-1-methyl-4-phenyl-3H-pyrido[1,2-c]pyrimidin-3-one C ₂₃ H ₃₃ N ₃ O
alfadexum alfadex	α-cyclodextrin C ₃₆ H ₆₀ O ₃₀

¹ *Off. Rec. Wild Hlth Org.*, 1955, **60**, 3 (Resolution EB15 R7); 1969, **1973**, 10 (Resolution EB43.R9).

² Other lists of recommended international nonproprietary names can be found in *Cumulative List No. 7, 1988*.

alteplasm alteplase	plasminogen activator (human tissue-type 2-chain form protein moiety) $C_{2736}H_{4174}N_{914}O_{824}S_{45}$
ambamustinum ambamustine	<i>N</i> -[3-[<i>m</i> -(bis(2-chloroethyl)amino)phenyl]- <i>N</i> -(3-(<i>p</i> -fluorophenyl)- <i>L</i> -alanyl)- <i>L</i> -alanyl]- <i>L</i> -methionine, ethyl ester $C_{29}H_{38}Cl_2FN_4O_4S$
ambasilidum ambasilide	3-(<i>p</i> -aminobenzoyl)-7-benzyl-3,7-diazabicyclo[3.3.1]nonane $C_{21}H_{23}N_3O$
amilomerum amilomer	microspheres produced by reaction of partially hydrolysed starch with epichlorhydrin, quickly degradable by amylase (with a half-life of less than 120 minutes) The name is followed by a hyphenated numerical code in which the number preceding the hyphen indicates the half-life in minutes and that following the hyphen indicates the mean diameter of the microspheres in μm . e.g. <i>amilomer 25-45</i> has a half-life of 25 minutes and a mean diameter of 45 μm . The methods of determining these parameters are approved by the competent national authority.
anistreplasm anistreplase	anisoylated (human) lys-plasminogen streptokinase activator complex (1 : 1)
antithrombinum III antithrombin III	antithrombin III. The source of the product should be indicated.
apafantum apafant	4-[3-[4-(<i>o</i> -chlorophenyl)-9-methyl-6 <i>H</i> -thieno[3,2- <i>f</i>]-s-triazolo[4,3- <i>a</i>]-[1,4]diazepin-2-yl]propionyl]morpholine $C_{22}H_{22}ClN_5O_2S$
apraclonidinum apraclonidine	2-[(4-amino-2,6-dichlorophenyl)imino]imidazolidine $C_9H_{10}Cl_2N_4$
argimesnum argimesna	<i>L</i> -arginine mono(2-mercaptoethanesulfonate) $C_8H_{20}N_4O_6S_2$
arpromidinum arpromidine	(\pm)-1-[3-(<i>p</i> -fluorophenyl)-3-(2-pyridyl)propyl]-3-(3-imidazol-4-ylpropyl)-guanidine $C_{21}H_{23}FN_8$
atosibanum atosiban	1-(3-mercaptopropionic acid)-2-[3-(<i>p</i> -ethoxyphenyl)- <i>D</i> -alanine]-4- <i>L</i> -threonine-8- <i>L</i> -ornithineoxycytocin $C_{43}H_{67}N_{11}O_{12}S_2$
azetirelinum azetirelin	(-)- <i>N</i> -[[[(2 <i>S</i>)-4-oxo-2-azetidiny]carbonyl]- <i>L</i> -histidyl- <i>L</i> -prolinamide $C_{19}H_{20}N_6O_4$
barmastinum barmastine	3-[2-[4-[(3-furfuryl-3 <i>H</i> -imidazo[4,5- <i>b</i>]pyridin-2-yl)amino]piperidino]ethyl]-2-methyl-4 <i>H</i> -pyrido[1,2- <i>a</i>]pyrimidin-4-one $C_{27}H_{28}N_7O_3$
baxitozinum baxitozine	(<i>E</i>)-3-(3,4,5-trimethoxybenzoyl)acrylic acid $C_{13}H_{14}O_6$
bepafantum bepafant	4-[[[6-(<i>o</i> -chlorophenyl)-8,9-dihydro-1-methyl-4 <i>H</i> ,7 <i>H</i> -cyclopenta[4.5]thieno[3,2- <i>f</i>]-s-triazolo[4,3- <i>a</i>][1,4]diazepin-8-yl]carbonyl]morpholine $C_{23}H_{22}ClN_5O_2S$
beraprostum beraprost	(\pm)-(1 <i>R</i> *,2 <i>R</i> *,3 <i>aS</i> *,8 <i>bS</i> *)-2,3,3 <i>a</i> ,8 <i>b</i> -tetrahydro-2-hydroxy-1-[(<i>E</i>)-(3 <i>S</i> *)-3-hydroxy-4-methyl-1-octen-6-ynyl]-1 <i>H</i> -cyclopenta[<i>b</i>]benzofuran-5-butiric acid $C_{24}H_{30}O_5$

betiatidium betiatide	<i>N</i> -[<i>N</i> -[<i>N</i> -(mercaptoacetyl)glycyl]glycyl]glycine benzoate (ester) C ₁₅ H ₁₇ N ₃ O ₄ S
binfloxacinum binfloxacin	7-(1,4-diazabicyclo[3.2.2]non-4-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid C ₁₉ H ₂₃ FN ₂ O ₃
binizolastum binizolast	1-(piperidinomethyl)-4-propyl- <i>s</i> -triazolo[4,3- <i>a</i>]quinazolin-5(4 <i>H</i>)-one C ₁₈ H ₂₃ N ₅ O
bisaramilum bisaramil	<i>syn</i> -3-ethyl-7-methyl-3,7-diazabicyclo[3.3.1]non-9-yl <i>p</i> -chlorobenzoate C ₁₇ H ₂₃ ClN ₂ O ₂
bretazenilum bretazenil	<i>tert</i> -butyl (<i>S</i>)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9 <i>H</i> -imidazo-[1,5- <i>a</i>]pyrrolo[2,1- <i>c</i>][1,4]benzodiazepine-1-carboxylate C ₁₈ H ₂₀ BrN ₃ O ₃
brivudinum brivudine	(<i>E</i>)-5-(2-bromovinyl)-2'-deoxyuridine C ₁₁ H ₁₃ BrN ₂ O ₅
bunaprolastum bunaprolast	2-butyl-4-methoxy-1-naphthol acetate C ₁₇ H ₂₀ O ₃
cefcanelum cefcanel	(6 <i>R</i> ,7 <i>R</i>)-7-[(<i>R</i>)-mandelamido]-3-[[5-methyl-1,3,4-thiadiazol-2-yl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid C ₁₉ H ₁₈ N ₄ O ₆ S ₃
cefcanelum daloxatum cefcanel daloxate	2,3-dihydroxy-2-butenyl (6 <i>R</i> ,7 <i>R</i>)-7-[(<i>R</i>)-mandelamido]-3-[[5-methyl-1,3,4-thiadiazol-2-yl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, cyclic 2,3-carbonate, ester with L-alanine C ₂₇ H ₂₇ N ₅ O ₉ S ₃
cefprozilum cefprozil	(6 <i>R</i> ,7 <i>R</i>)-7-[(<i>R</i>)-2-amino-2-(<i>p</i> -hydroxyphenyl)acetamido]-8-oxo-3-(1-propenyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid C ₁₈ H ₁₉ N ₃ O ₆ S
cefquinomum cefquinome	1-[[5-methyl-1,3,4-thiadiazol-2-yl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid C ₂₃ H ₂₄ N ₄ O ₆ S ₂
ceftibutenum ceftibuten	(+)-[(6 <i>R</i> ,7 <i>R</i>)-7-[(<i>Z</i>)-2-(2-amino-4-thiazolyl)-4-carboxycrotonamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid C ₁₈ H ₁₄ N ₄ O ₆ S ₂
cilofunginum cilofungin	1-[(4 <i>R</i> ,5 <i>R</i>)-4,5-dihydroxy- <i>N</i> ² -[<i>p</i> -(octyloxy)benzoyl]-L-ornithine]echinocandin B or (4 <i>R</i> ,5 <i>R</i>)-4,5-dihydroxy- <i>N</i> ² -[<i>p</i> -(octyloxy)benzoyl]-L-ornithyl-L-threonyl- <i>trans</i> -4-hydroxy-L-prolyl-(<i>S</i>)-4-hydroxy-4-(<i>p</i> -hydroxyphenyl)-L-threonyl-L-threonyl-(3 <i>S</i> ,4 <i>S</i>)-3-hydroxy-4-methyl-L-proline cyclic (6→1)-peptide C ₄₈ H ₇₁ N ₇ O ₁₇
cisconazolum cisconazole	(±)- <i>cis</i> -1-[[3-[(2,6-difluorobenzyl)oxy]-5-fluoro-2,3-dihydrobenzo[<i>b</i>]thien-2-yl]methyl]imidazole C ₁₁ H ₁₃ F ₃ N ₂ OS
clarithromycinum clarithromycin	6- <i>O</i> -methylerythromycin C ₂₆ H ₄₀ NO ₁₃

colestololum colestolone	3 β -hydroxy-5 α -cholest-8(14)-en-15-one C ₂₇ H ₄₄ O ₂
colextranum colextran	dextran 2-(diethylamino)ethyl ether
cyromazinum cyromazine	cyclopropylmelamine C ₆ H ₁₀ N ₆
daptomycinum daptomycin	<i>N</i> -decanoyl-L-tryptophyl-L-asparaginyll-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-L-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine, ϵ -lactone C ₇₂ H ₁₀₁ N ₁₇ O ₂₆
delfaprazinum delfaprazine	1-(α^2 -phenyl-2,5-xylyl)piperazine C ₁₈ H ₂₂ N ₂
delmopinolum delmopinol	(\pm)-3-(4-propylheptyl)-4-morpholineethanol C ₁₈ H ₃₃ NO ₂
dexmedetomidinum dexmedetomidine	(+)-4-[(<i>R</i>)- α ,2,3-trimethylbenzyl]imidazole C ₁₃ H ₁₆ N ₂
diprafenonum diprafenone	(\pm)-2'-[2-hydroxy-3-(<i>tert</i> -pentylamino)propoxy]-3-phenylpropiofenone C ₂₃ H ₃₁ NO ₃
dizocilpinum dizocilpine	(+)-10,11-dihydro-5-methyl-5 <i>H</i> -dibenzo[<i>a,d</i>]cyclohepten-5,10-imine C ₁₆ H ₁₆ N
docarpaminum docarpamine	(-)-(S)-2-acetamido-N-(3,4-dihydroxyphenethyl)-4-(methylthio)butyramide bis(ethyl carbonate) (ester) C ₂₇ H ₃₆ N ₂ O ₈ S
dopropidilum dopropidil	1-[1-(isobutoxymethyl)-2-[[1-(1-propynyl)cyclohexyl]oxy]ethyl]pyrrolidine C ₂₆ H ₃₅ NO ₂
doretinelum doretinel	(\pm)- <i>p</i> -[(<i>E</i>)-2-(5,6,7,8-tetrahydro-7-hydroxy-5,8,8-tetramethyl-2-naphthyl)-propenyl]benzyl alcohol C ₂₄ H ₃₀ O ₂
dumorelinum dumorelin	27-L-leucine-44a-glycinegrowth hormone-releasing factor (human) C ₇₁₈ H ₁₀₆₂ N ₇₂ O ₆₈
edelfosinum edelfosine	choline hydroxide, (\pm)-2-methoxy-3-(octadecyloxy)propyl hydrogen phosphate, inner salt or 2- <i>O</i> -methyl-1- <i>O</i> -octadecyl- <i>rac</i> -glycero-3-phosphocholine C ₂₇ H ₅₈ NO ₆ P
efaroxanum efaroxan	(\pm)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline C ₁₃ H ₁₆ N ₂ O
elbanizinium elbanizine	1-[2-[(2,6-dimethyl-3-nitro-4-pyridyl)amino]ethyl]-4-(diphenylmethyl)-piperazine C ₂₆ H ₃₁ N ₅ O ₂
elnadipinum elnadipine	isopropyl (-)-(S)-4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-5-(1,3,4-oxadiazol-2-yl)nicotinate C ₁₉ H ₁₉ Cl ₂ N ₃ O ₃

emedastinum emedastine	1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1 <i>H</i> -1,4-diazepin-1-yl)benzimidazole C ₁₇ H ₂₆ N ₄ O
endixaprinum endixaprine	1-[6-(2,4-dichlorophenyl)-3-pyridazinyl]-4-piperidinol C ₁₃ H ₁₅ Cl ₂ N ₃ O
epicriptinum epicriptine	9,10α-dihydro-13'-epi-β-ergocryptine or (13' <i>R</i>)-9,10α-dihydro-β-ergocryptine C ₃₂ H ₄₃ N ₆ O ₅
erbulozolum erbulozole	ethyl (±)- <i>cis-p</i> -[[[2-(imidazol-1-ylmethyl)-2-(<i>p</i> -methoxyphenyl)-1,3-dioxolan-4-yl]methyl]thio]carbanilate C ₂₄ H ₂₇ N ₃ O ₅ S
esafloxacinum esafloxacin	(±)-7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid C ₁₅ H ₁₇ FN ₄ O ₃
etrabaminum etrabamine	4,5,6,7-tetrahydro-6-(methylamino)benzothiazole C ₈ H ₁₂ N ₂ S
famiraprinii chloridum famiraprinium chloride	6-amino-1-(3-carboxypropyl)-5-methyl-3-phenylpyridazinium chloride C ₁₅ H ₁₆ ClN ₃ O ₂
fiacitabinum fiacitabine	1-(2-deoxy-2-fluoro-β- <i>D</i> -arabinofuranosyl)-5-iodocytosine C ₉ H ₁₁ FIN ₃ O ₄
flerobuterolum flerobuteroI	α-[(<i>tert</i> -butylamino)methyl]- <i>o</i> -fluorobenzyl alcohol C ₁₂ H ₁₈ FNO
fluparoxanum fluparoxan	(3 <i>aS</i> ,9 <i>aS</i>)-5-fluoro-2,3,3 <i>a</i> ,9 <i>a</i> -tetrahydro-1 <i>H</i> -[1,4]benzodioxino[2,3- <i>c</i>]pyrrole C ₁₀ H ₁₀ FNO ₂
fronepidilum fronepidil	1-[1-(isobutoxymethyl)-2-[(1-methyl-1-phenyl-2-propynyl)oxy]ethyl]pyrrolidine C ₂₁ H ₃₁ NO ₂
gadopenamidum gadopenamide	[<i>N,N</i> -bis[2-[(carboxymethyl)[(morpholinocarbonyl)methyl]amino]ethyl]-glycinato(3-)]gadolinium C ₂₂ H ₃₄ GdN ₅ O ₁₀
galtifeninum galtifenin	[[[(2,6-diethyl-3-iodophenyl)carbamoyl]methyl]imino]diacetic acid C ₁₈ H ₂₁ IN ₂ O ₅
gapromidinum gapromidine	1-(3-imidazol-4-ylpropyl)-3-[2-(2-pyridylamino)ethyl]guanidine C ₁₄ H ₂₁ N ₇
glisentidum glisentide	1-cyclopentyl-3-[[<i>p</i> -[2-(<i>o</i> -anisamido)ethyl]phenyl]sulfonyl]urea C ₂₂ H ₂₇ N ₃ O ₅ S
granisetronum granisetron	1-methyl- <i>N</i> -(<i>endo</i> -9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1 <i>H</i> -indazole-3-carboxamide C ₁₈ H ₂₄ N ₄ O
ibafloxacinum ibafloxacin	9-fluoro-6,7-dihydro-5,8-dimethyl-1-oxo-1 <i>H</i> ,5 <i>H</i> -benzo[<i>i</i>]quinolizine-2-carboxylic acid C ₁₅ H ₁₄ FNO ₃

Recommended International
Nonproprietary Name (Latin, English)

Chemical Name or Description and Molecular Formulae

imidaprilum imidapril	(4 <i>S</i>)-3-[(2 <i>S</i>)- <i>N</i> -[(1 <i>S</i>)-1-carboxy-3-phenylpropyl]alanyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic acid, 3-ethyl ester $C_{20}H_{27}N_3O_6$
imirestatum imirestat	2,7-difluorospiro[fluorene-9,4'-imidazolidine]-2',5'-dione $C_{15}H_8F_2N_2O_2$
inaperisonum inaperisone	(±)-4'-ethyl-2-methyl-3-(1-pyrrolidinyl)propiofenone $C_{16}H_{23}NO$
iotrisidum iotriside	(±)- <i>N,N'</i> -bis(2,3-dihydroxypropyl)-2,4,6-triiodo- <i>N</i> -methyl-1,3,5-benzenetri-carboxamide $C_{16}H_{20}I_3N_3O_7$
ioxilanum ioxilan	<i>N</i> -(2,3-dihydroxypropyl)-5-[<i>N</i> -(2,3-dihydroxypropyl)acetamido]- <i>N'</i> -(2-hydroxyethyl)-2,4,6-triiodoisophthalamide $C_{19}H_{24}I_3N_3O_8$
irtemazolum irtemazole	(±)-5-(α -imidazol-1-ylbenzyl)-2-methylbenzimidazole $C_{16}H_{16}N_4$
isbogrelum isbogrel	(<i>E</i>)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid $C_{16}H_{16}NO_2$
ivarimodum ivarimod	4-[[[(3 <i>aR</i> ,3 <i>bS</i> ,5 <i>aR</i> ,6 <i>R</i> ,9 <i>aR</i> ,9 <i>bR</i> ,11 <i>R</i> ,11 <i>aR</i>)-1,2,3,3 <i>a</i> ,4,5,5 <i>a</i> ,6,7,8,9,9 <i>a</i> ,9 <i>b</i> ,10,11,11 <i>a</i> -hexadecahydro-2-(2-hydroxyethyl)-12-isopropyl-6,9 <i>a</i> -dimethyl-1,3-dioxo-3 <i>b</i> ,11-etheno-3 <i>bH</i> -naphth[2,1- <i>e</i>]isoindol-6-yl]carbonyl]morpholine $C_{30}H_{44}N_2O_4$
lansoprazolum lansoprazole	2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole $C_{16}H_{14}F_3N_3O_2S$
laprafyllinum laprafylline	8-[2-[4-(diphenylmethyl)-1-piperazinyl]ethyl]-3-isobutyl-1-methylxanthine $C_{28}H_{38}N_4O_2$
locicortoloni dicibas locicortolone dicibate	9,11 β -dichloro-21-hydroxy-16 α -methylpregna-1,4-diene-3,20-dione dicyclohexylmethyl carbonate $C_{36}H_{50}Cl_2O_5$
lodelabenum lodelaben	(±)-2-chloro-4-(1-hydroxyoctadecyl)benzoic acid $C_{25}H_{41}ClO_3$
loracarbefum loracarbef	(6 <i>R</i> ,7 <i>S</i>)-7-[(<i>R</i>)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-1-azabi-cyclo[4.2.0]oct-2-ene-2-carboxylic acid $C_{18}H_{18}ClN_3O_4$
loreclezolum loreclezole	(<i>Z</i>)-1-(β ,2,4-trichlorostyryl)-1 <i>H</i> -1,2,4-triazole $C_{10}H_6Cl_3N_3$
lornoxicamum lornoxicam	6-chloro-4-hydroxy-2-methyl- <i>N</i> -2-pyridyl-2 <i>H</i> -thieno[2,3- <i>e</i>]-1,2-thiazine-3-carboxamide 1,1-dioxide $C_{13}H_{10}ClN_3O_4S_2$
lorpiprazolum lorpiprazole	(±)- <i>cis</i> -5,5 <i>a</i> ,6,7,8,8 <i>a</i> -hexahydro-3-[2-[4-(α,α,α -trifluoro- <i>m</i> -tolyl)-1-piperazinyl]ethyl]cyclopenta[3,4]pyrrolo[2,1- <i>c</i>]- <i>s</i> -triazole $C_{21}H_{26}F_3N_5$
manidipinum manidipine	2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl (±)-1,4-dihydro-2,6-dimethyl-4-(<i>m</i> -nitrophenyl)-3,5-pyridinedicarboxylate $C_{35}H_{38}N_4O_6$

meropenemum meropenem	(4 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-3-[[[(3 <i>S</i> ,5 <i>S</i>)-5-(dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6-[(1 <i>R</i>)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid $C_{17}H_{25}N_3O_5S$
mertiatidum mertiatide	<i>N</i> -[<i>N</i> -[<i>N</i> -(mercaptoacetyl)glycyl]glycyl]glycine $C_8H_{13}N_3O_5S$
metalkonii chloridum metaikonium chloride	benzyl[(dodecylcarbamoyl)methyl]dimethylammonium chloride $C_{23}H_{41}ClN_2O$
methoprenum methoprene	isopropyl (2 <i>E</i> ,4 <i>E</i>)-(7 <i>S</i>)-11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate $C_{18}H_{34}O_3$
milnacipranum milnacipran	(±)- <i>cis</i> -2-(aminomethyl)- <i>N,N</i> -diethyl-1-phenylcyclopropanecarboxamide $C_{18}H_{21}N_2O$
mirosamicinum mirosamicin	14-hydroxymycinamicin I or (-)-(1 <i>R</i> ,2 <i>S</i> ,3 <i>R</i> ,6 <i>E</i> ,8 <i>S</i> ,9 <i>S</i> ,10 <i>S</i> ,12 <i>R</i> ,14 <i>E</i> ,16 <i>S</i>)-2-[[[(6-deoxy-2,3-di- <i>O</i> -methyl-β- <i>D</i> -allopyranosyl)oxy]methyl]-3-ethyl-2-hydroxy-8,10,12-trimethyl-9-[[[3,4,6-trideoxy-3-(dimethylamino)-β- <i>D</i> -xylo-hexopyranosyl]oxy]-4,17-dioxabicyclo[14.1.0]heptadeca-6,14-diene-5,13-dione $C_{37}H_{61}NO_{13}$
mitoflaxonom mitoflaxone	4-oxo-2-phenyl-4 <i>H</i> -1-benzopyran-8-acetic acid $C_{17}H_{12}O_4$
moexiprilum moexipril	(3 <i>S</i>)-2-[(2 <i>S</i>)- <i>N</i> -[(1 <i>S</i>)-1-carboxy-3-phenylpropyl]alaninyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, 2-ethyl ester $C_{27}H_{34}N_2O_7$
moxiraprinum moxirapine	<i>p</i> -[5-methyl-6-[(2-morpholinoethyl)amino]-3-pyridazinyl]phenol $C_{17}H_{22}N_4O_2$
muroderminum murodermin	urogastrone (mouse salivary gland) or epidermal growth factor (mouse salivary gland)
muromonabum-CD3 muromonab-CD3	a biochemically purified IgG _{2a} immunoglobulin consisting of a heavy chain of approx. 50,000 daltons and a light chain of approx. 25,000 daltons. It is manufactured by a process involving the fusion of mouse myeloma cells to lymphocytes from immunized animals to produce a hybridoma which secretes antigen-specific antibodies to the T3 antigen of human T-lymphocytes.
nanterinonum nanterinone	6-(2,4-dimethylimidazol-1-yl)-8-methylcarbostyryl $C_{15}H_{13}N_3O$
napirimumus napirimus	1-methyl-4-(1-naphtholyl)pyrrole-2-carboxylic acid $C_{17}H_{13}NO_3$
natrii pentosani polysulfas pentosan polysulfate sodium	(1→4)-β- <i>D</i> -xylan 2,3-bis(hydrogen sulfate), sodium salt $(C_5H_8Na_2O_{10}S_2)_n$
naxagolidum naxagolide	(+)-(4 <i>aR</i> ,10 <i>bR</i>)-3,4,4 <i>a</i> ,5,6,10 <i>b</i> -hexahydro-4-propyl-2 <i>H</i> -naphth[1,2- <i>b</i>]-1,4-oxazin-9-ol $C_{15}H_{21}NO_2$

*Recommended International
Nonproprietary Name (Latin, English)*

Chemical Name or Description and Molecular Formulae

nebracetamum nebracetam	(±)-4-(aminomethyl)-1-benzyl-2-pyrrolidinone $C_{12}H_{16}N_2O$
neldazosinum neldazosin	(±)-1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(3-hydroxybutyryl)piperazine $C_{18}H_{24}N_4O_4$
nelezaprinum nelezaprine	(E)-9-chloro-11-[3-(dimethylamino)propylidene]-6,11-dihydro-5H-pyrrolo[2,1-b][3]benzazepine $C_{18}H_{21}ClN_2$
nemadectinum nemadectin	(6R,23S,25S)-5-O-demethyl-28-deoxy-25-[(E)-1,3-dimethyl-1-butenyl]-6,28-epoxy-23-hydroxymilbemycin B $C_{34}H_{52}O_8$
nicaravenum nicaraven	(±)-N,N'-propylenebis[nicotinamide] $C_{18}H_{16}N_4O_2$
noberastinum noberastine	3-(5-methylfurfuryl)-2-(4-piperidylamino)-3H-imidazo[4,5-b]pyridine $C_{17}H_{21}N_5O$
nuvenzepinum nuvenzepine	6,11-dihydro-11-(1-methylisonipecotoyl)-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one $C_{19}H_{20}N_4O_2$
ondansetronum ondansetron	(±)-2,3-dihydro-9-methyl-3-[(2-methylimidazol-1-yl)methyl]carbazol-4(1H)-one $C_{18}H_{18}N_3O$
oxamisolum oxamisole	(±)-2,3,6,7-tetrahydro-2-phenylimidazo[1,2-a]pyridin-8(5H)-one, dimethyl acetal $C_{18}H_{26}N_2O_2$
pelretinum pelretin	(E,E,E)-p-[4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3,5-hexatrienyl]-benzoic acid $C_{23}H_{28}O_2$
pentamorphonum pentamorphone	7,8-didehydro-4,5a-epoxy-3-hydroxy-17-methyl-14-(pentylamino)morphinan-6-one $C_{27}H_{28}N_2O_3$
pentigetidum pentigetide	N ² -[1-[N-(N-L-α-aspartyl-L-seryl)-L-α-aspartyl-L-prolyl]-L-arginine $C_{22}H_{36}N_8O_{11}$
pentisomidum pentisomide	(±)-α-[2-(diisopropylamino)ethyl]-α-isobutyl-2-pyridineacetamide $C_{19}H_{33}N_3O$
perfomedilum perfomedil	(±)-2',4',6'-trimethoxy-4-(3-methylpiperidino)butyrophenone $C_{18}H_{25}NO_4$
phenylpropanolaminum phenylpropanolamine	(±)-norephedrine $C_9H_{13}NO$
pioglitazonum pioglitazone	(±)-5-[p-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione $C_{19}H_{26}N_2O_3S$

piroxantrone piroxantrone	5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]-ethyl]anthra[1,9- <i>cd</i>]pyrazol-6(2 <i>H</i>)-one $C_{21}H_{25}N_5O_4$
posatirelinum posatirelin	(2 <i>S</i>)- <i>N</i> -[(1 <i>S</i>)-1-[(2 <i>S</i>)-2-carbamoyl-1-pyrrolidinyl]carbonyl]-3-methylbutyl-6-oxopipecolamide $C_{17}H_{28}N_4O_4$
pravadolinum pravadoline	<i>p</i> -methoxyphenyl 2-methyl-1-(2-morpholinoethyl)indol-3-yl ketone $C_{23}H_{28}N_2O_3$
prifelonium prifelone	3,5-di- <i>tert</i> -butyl-4-hydroxyphenyl 2-thienyl ketone $C_{18}H_{24}O_2S$
quinaprilatum quinaprilat	(3 <i>S</i>)-2-[(<i>S</i>)- <i>N</i> -[(<i>S</i>)-1-carboxy-3-phenylpropyl]alanyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid $C_{23}H_{28}N_2O_5$
quineloranum quinelorane	(-)-(5 <i>aR</i> ,9 <i>aR</i>)-2-amino-5,5 <i>a</i> ,6,7,8,9,9 <i>a</i> ,10-octahydro-6-propylpyrido[2,3- <i>g</i>]quinazoline $C_{14}H_{22}N_4$
renzapridum renzapride	(±)- <i>endo</i> -4-amino- <i>N</i> -1-azabicyclo[3.3.1]non-4-yl-5-chloro- <i>o</i> -anisamide $C_{18}H_{22}ClN_2O_2$
ridogrelum ridogrel	(<i>E</i>)-5-[[[<i>α</i> -3-pyridyl- <i>m</i> -(trifluoromethyl)benzylidene]amino]oxy]valeric acid $C_{18}H_{17}F_3N_2O_3$
riluzolum riluzole	2-amino-6-(trifluoromethoxy)benzothiazole $C_8H_5F_3N_2OS$
romazaritum romazarit	2-[2-(<i>p</i> -chlorophenyl)-4-methyl-5-oxazolyl]methoxy]-2-methylpropionic acid $C_{13}H_{16}ClNO_4$
rosterolonum rosterolone	17β-hydroxy-1α-methyl-17-propyl-5α-androstan-3-one $C_{25}H_{38}O_2$
rotraxatum rotraxate	<i>p</i> -[[<i>trans</i> -4-(aminomethyl)cyclohexyl]carbonyl]hydrocinnamic acid $C_{17}H_{23}NO_3$
roxindolum roxindole	3-[4-(3,6-dihydro-4-phenyl-1(2 <i>H</i>)-pyridyl)butyl]indol-5-ol $C_{23}H_{26}N_2O$
saperconazolum saperconazole	(±)-1- <i>sec</i> -butyl-4-[<i>p</i> -[4-[<i>p</i> -[[[2 <i>R'</i> ,4 <i>S'</i>]-2-(2,4-difluorophenyl)-2-(1 <i>H</i> -1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-4'-1,2,4-triazolin-5-one $C_{35}H_{38}F_2N_8O_4$
sarmazenilum sarmazenil	ethyl 7-chloro-5,6-dihydro-5-methyl-6-oxo-4 <i>H</i> -imidazo-[1,5- <i>a</i>][1,4]benzodiazepine-3-carboxylate $C_{13}H_{14}ClN_3O_3$

semduramicinum semduramicin	(3 <i>R</i> ,4 <i>S</i> ,5 <i>S</i> ,6 <i>R</i> ,7 <i>S</i> ,22 <i>S</i>)-23,27-didemethoxy-2,6,22-tridemethyl-5,11-di- <i>O</i> -demethyl-6-methoxy-22-[[[(2 <i>S</i> ,5 <i>S</i> ,6 <i>R</i>)-tetrahydro-5-methoxy-6-methyl-2 <i>H</i> -pyran-2-yl]oxy]lonomycin A or (2 <i>R</i> ,3 <i>S</i> ,4 <i>S</i> ,5 <i>R</i> ,6 <i>S</i>)-tetrahydro-2,4-dihydroxy-6-[(1 <i>R</i>)-1-[(2 <i>S</i> ,5 <i>R</i> ,7 <i>S</i> ,8 <i>R</i> ,9 <i>S</i>)-9-hydroxy-2,8-dimethyl-2-[(2 <i>R</i> ,5 <i>S</i>)-tetrahydro-5-methyl-5-[(2 <i>R</i> ,3 <i>S</i> ,5 <i>R</i>)-tetrahydro-5-[(2 <i>S</i> ,3 <i>S</i> ,5 <i>R</i> ,6 <i>S</i>)-tetrahydro-6-hydroxy-3,5,6-trimethyl-2 <i>H</i> -pyran-2-yl]-3-[[[(2 <i>S</i> ,5 <i>S</i> ,6 <i>R</i>)-tetrahydro-5-methoxy-6-methyl-2 <i>H</i> -pyran-2-yl]oxy]-2-furyl]-2-furyl]-1,6-dioxaspiro[4.5]dec-7-yl]ethyl)-5-methoxy-3-methyl-2 <i>H</i> -pyran-2-acetic acid C ₄₃ H ₇₈ O ₁₈
sergolexolum sergolexole	<i>trans</i> -4-methoxycyclohexyl 1-isopropyl-6-methylergoline-8β-carboxylate C ₂₆ H ₃₆ N ₂ O ₃
siguazodanum siguazodan	2-cyano-1-methyl-3-[<i>p</i> -(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]guanidine C ₁₄ H ₁₆ N ₆ O
sitalidonum sitalidone	(±)-2-chloro-4'-hydroxy-5-(2-hydroxy-1-methyl-5-oxo-2-pyrrolidinyl)-3',5'-diisopropylbenzenesulfonanilide C ₂₃ H ₂₈ ClN ₂ O ₅ S
spiraprilatum spiraprilat	(8 <i>S</i>)-7-[(<i>S</i>)- <i>N</i> -[(<i>S</i>)-1-carboxy-3-phenylpropyl]alanyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid C ₂₀ H ₂₈ N ₂ O ₅ S ₂
spirotyllinum spirotylline	8-phenethyl-3-[(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxopurin-7-yl)acetyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one C ₂₈ H ₂₈ N ₄ O ₅
sumatriptanum sumatriptan	3-[2-(dimethylamino)ethyl]- <i>N</i> -methylindole-5-methanesulfonamide C ₁₄ H ₂₁ N ₃ O ₂ S
tabilautidum tabilautide	<i>threo</i> -6-carbamoyl- <i>N</i> ² -[<i>N</i> -(<i>N</i> -lauroyl-L-alanyl)- <i>D</i> ;-L-glutamyl]-L-lysine C ₂₇ H ₄₉ N ₅ O ₆
tandospironum tandospirone	(1 <i>R</i> *,2 <i>S</i> *,3 <i>R</i> *,4 <i>S</i> *)- <i>N</i> -[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3-norbornanedicarboximide C ₂₁ H ₂₉ N ₅ O ₂
tazanolastum tazanolast	butyl 3'-(1 <i>H</i> -tetrazol-5-yl)oxanilate C ₁₃ H ₁₆ N ₄ O ₃
tazobactamum tazobactam	(2 <i>S</i> ,3 <i>S</i> ,5 <i>R</i>)-3-methyl-7-oxo-3-(1 <i>H</i> -1,2,3-triazol-1-ylmethyl)-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid, 4,4-dioxide C ₁₀ H ₁₂ N ₄ O ₅ S
technetium (^{99m} Tc) sestamibi technetium (^{99m} Tc) sestamibi	hexakis(2-methoxy-2-methylpropyl isocyanide)[^{99m} Tc]technetium(1+) C ₂₄ H ₄₈ N ₆ O ₆ ^{99m} Tc
tedisamilum tedisamil	3',7'-bis(cyclopropylmethyl)spiro[cyclopentane-1,9'-[3,7]diazabicyclo[3.3.1]nonane] C ₁₉ H ₃₂ N ₂
temafloxacinum temafloxacin	(±)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid C ₂₁ H ₁₈ F ₃ N ₃ O ₃

temurtidum temurtide	2-acetamido-3-O-[[[(1 <i>R</i>)-1-[(1 <i>S</i> ,2 <i>R</i>)-1-[(1 <i>R</i>)-1-carbamoyl-3-carboxypropyl]-carbamoyl]-2-hydroxypropyl]carbamoyl]ethyl]-2-deoxy- α -glucopyranose $C_{20}H_{34}N_4O_{12}$
thrombinum thrombin	thrombin or E.C. 3.4.21.5 The source of the product should be indicated
thymocartinum thymocartin	<i>N</i> -[<i>N</i> -(<i>N</i> ² -L-arginyl-L-lysyl)-L- α -aspartyl]-L-valine $C_{21}H_{40}N_8O_7$
tomelukastum tomelukast	2'-hydroxy-3'-propyl-4'-[4-(1 <i>H</i> -tetrazol-5-yl)butoxy]acetophenone $C_{16}H_{22}N_4O_3$
tosufloxacinum tosufloxacin	(\pm)-7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid $C_{18}H_{13}F_3N_4O_3$
trandolaprilatum trandolaprilat	(2 <i>S</i> ,3 <i>aR</i> ,7 <i>aS</i>)-1-[(<i>S</i>)- <i>N</i> -[(<i>S</i>)-1-carboxy-3-phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid $C_{23}H_{30}N_2O_5$
troxolamidum troxolamide	3-[[[2,3-dihydroxy-1-(hydroxymethyl)propyl]carbamoyl]-2,2,5,5-tetramethyl-1-pyrrolidinyl]oxy $C_{13}H_{23}N_2O_5$
umespironum umespirone	<i>N</i> -butyl- <i>N</i> '-[4-[4-(<i>o</i> -methoxyphenyl)-1-piperazinyl]butyl]-2,2-dimethyl-1,1,3,3-propanetetra-carboxylic 1,3 : 1,3-dimide $C_{28}H_{40}N_4O_5$
vapiprostum vapiprost	(+)-(Z)-7-[(1 <i>R</i> ,2 <i>R</i> ,3 <i>S</i> ,5 <i>S</i>)-3-hydroxy-5-[(<i>p</i> -phenylbenzyl)oxy]-2-piperidinocyclopentyl]-4-heptenoic acid $C_{30}H_{38}NO_4$
venlafaxinum venlafaxine	(\pm)-1-[α -[(dimethylamino)methyl]- <i>p</i> -methoxybenzyl]cyclohexanol $C_{17}H_{27}NO_2$
vinmegallatum vinmegallate	17,18-didehydro-3 α ,16 α -eburnamenine-14-methanol 3,4,5-trimethoxybenzoate (ester) $C_{30}H_{32}N_2O_5$
zardaverinum zardaverine	6-[4-(difluoromethoxy)-3-methoxyphenyl]-3(2 <i>H</i>)-pyridazinone $C_{17}H_{10}F_2N_2O_3$
zilpaterolum zilpaterol	(\pm)- <i>trans</i> -4,5,6,7-tetrahydro-7-hydroxy-6-(isopropylamino)imidazo-[4,5,1- <i>jk</i>][1]benzazepin-2(1 <i>H</i>)-one $C_{14}H_{18}N_3O_2$

AMENDMENTS TO PREVIOUS LISTS

WHO Chronicle Vol. 9, 1955

Recommended International Nonproprietary Names (Rec. INN): List 1

p. 185	<i>delete</i>	<i>insert</i>
	acidum aminoaceticum aminoacetic acid	glycinum glycine
p. 185	acidum glutamicum glutamic acid	<i>replace the chemical name by the following:</i> L-glutamic acid

WHO Chronicle Vol. 13, No. 12, 1959

Recommended International Nonproprietary Names (Rec. INN): List 3

p. 469	methioninum methionine	<i>replace the chemical name by the following:</i> L-methionine
--------	---------------------------	--

Supplement to WHO Chronicle Vol. 20, No. 11, 1966

Recommended International Nonproprietary Names (Rec. INN): List 6

p. 431	quinbolonium quinbolone	<i>replace the chemical name by the following:</i> 17 β -(1-cyclopenten-1-yloxy)androsta-1,4-dien-3-one
--------	----------------------------	--

WHO Chronicle Vol. 26, No. 10, 1972

Recommended International Nonproprietary Names (Rec. INN): List 12

p. 481	polidocanolum polidocanol	<i>delete the whole entry</i>
--------	------------------------------	-------------------------------

Supplement to WHO Chronicle Vol. 36, No. 6, 1982

Recommended International Nonproprietary Names (Rec. INN): List 22

p. 2	avilamycinum avilamycin	<i>replace the chemical name by the following:</i> consists mainly of avilamycin A or O-(1R)-4-C-acetyl-6-deoxy-2,3-O-methylene- β -galactopyranosylidene-(1 \rightarrow 3-4)-2-O-(2-methyl-1-oxopropyl)- α -L-lyxopyranosyl O-2,6-dideoxy-4-O-(3,5-dichloro-4-hydroxy-2-methoxy-6-methylbenzoyl)- β -D-arabino-hexopyranosyl-(1 \rightarrow 4)-O-2,6-dideoxy- β -D-arabino-hexopyranosylidene-(1 \rightarrow 3-4)-O-2,6-dideoxy-3-C-methyl- β -D-arabino-hexopyranosyl-(1 \rightarrow 3)-O-6-deoxy-4-O-methyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,6-di-O-methyl- β -D-mannopyranoside
------	----------------------------	---

p. 2 *delete*

cadexomerum iodum
cadexomer iodine

product of reaction of dextrin with epichlorohydrin coupled with ion-exchange groups and iodine

insert

cadexomerum
cadexomer

carboxymethylated microspheres produced by reaction of partially hydrolysed starch with epichlorohydrin; slowly degradable by amylase (with a half-life of more than 120 minutes)
Each cadexomer name is followed by a number referring to the mean diameter in μm of the microspheres: e.g. *cadexomer 110, 200* The method of determining this parameter is approved by the competent national authority.

Supplement to WHO Chronicle Vol. 37, No. 6, 1983

Recommended International Nonproprietary Names (Rec. INN): List 23

p. 3 *delete*

cholini glycerophosphas
choline glycerophosphate

insert

cholini alfosceras
choline alfoscerate

Supplement to WHO Chronicle Vol. 38, No. 6, 1984

Recommended International Nonproprietary Names (Rec. INN): List 24

p. 2 aprotininum
aprotinin

replace the chemical name and the molecular formula by the following:

Arg-Pro-Asp-Phe-HCys-Leu-Glu-Pro-Pro-Tyr-Thr-Gly-Pro-HCys-Lys-Ala-Arg-Ile-Ile-Arg-Tyr-Phe-Tyr-Asn-Ala-Lys-Ala-Gly-Leu-HCys-Gln-Thr-Phe-Val-Tyr-Gly-Gly-HCys-Arg-Ala-Lys-Arg-Asn-Asn-Phe-Lys-Ser-Ala-Glu-Asn-HCys-Met-Arg-Thr-HCys-Gly-Gly-Ala cyclic (5→55), (14→38), (30→51)-tris(disulfide)
 $\text{C}_{238}\text{H}_{432}\text{N}_{84}\text{O}_{78}\text{S}_7$

p. 4 eldexomerum
eldexomer

replace the definition by the following:

microspheres produced by reaction of partially hydrolysed starch with epichlorohydrin, slowly degradable by amylase (with a half-life of more than 120 minutes)

Each eldexomer name is followed by a number referring to the mean diameter in μm of the microspheres e.g. *eldexomer 60*. The method of determining this parameter is approved by the competent national authority.

p. 6 levocabastinum
levocabastine

replace the chemical name by:

(-)-(3*S*,4*R*)-1-(*cis*-4-cyano-4-(*p*-fluorophenyl)cyclohexyl)-3-methyl-4-phenylisonipecotic acid

Supplement to WHO Chronicle Vol. 39, No. 5, 1985

Recommended International Nonproprietary Names (Rec. INN): List 25

p. 10 pimelauidum
pimelauid

replace the chemical name by the following.

threo-6-carbamoyl-*N*²-[*N*-(*N*-lauroyl-L-alanyl)-D- γ -glutamyl]-*N*⁶-glycyl-DL-lysine

Supplement to WHO Chronicle Vol. 40, No. 6, 1986

Recommended International Nonproprietary Names (Rec. INN): List 26

p. 7 pirarubicinum
pirarubicin

replace the chemical name by the following:

(8*S*,10*S*)-10-[[3-amino-2,3,6-trideoxy-4-*O*-(2*R*-tetrahydro-2*H*-pyran-2-yl)- α -L-lyxo-hexopyranosyl]oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione

WHO Drug Information Vol. 1, No. 4, 1987

Recommended International Nonproprietary Names (Rec. INN): List 27

- | | | |
|------|-----------------------------|--|
| p. 7 | niguldipinum
niguldipine | <i>replace the chemical name by the following:</i>
(+)-(S)-3-(4,4-diphenylpiperidino)propyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate |
|------|-----------------------------|--|

WHO Drug Information Vol. 2, No. 3, 1988

Recommended International Nonproprietary Names (Rec. INN): List 28

- | | | |
|--------|--|--|
| p. 164 | <i>delete</i>
bendacololum
bendacolol | <i>insert</i>
bendacalolum
bendacalol |
| p. 164 | <i>delete</i>
clipoxaminum
clipoxamine | <i>insert</i>
cliropaminum
cliropamine |
| p. 166 | pemedolacum
pemedolac | <i>replace the chemical name by the following:</i>
(±)-cis-4-benzyl-1-ethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid |